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Abstract: Patients who have atrial fibrillation (AF) have increased thromboembolic risk. This risk is mitigated through
use of anticoagulants, traditionally with vitamin K antagonists such as warfarin, and more recently with drugs such as
Xa and thrombin inhibitors. Since anticoagulants increase the risk of bleeding, uncertainty exists regarding their use in
the perioperative period. The risk of thromboembolism for each patient must be balanced against risk of bleeding;
anticoagulation medication may be continued, replaced with a short-acting alternative or withheld entirely. Until
recently, evidence on best management relied on expert opinion and observational studies. The recent publication of
a randomised, double-blind, placebo-controlled trial (BRIDGE) has added important information to the knowledge base.
Trial registration: BRIDGE ClinicalTrials.gov, NCT00786474
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Background
Every year, approximately 10 % of warfarinised patients
with AF present for surgery or invasive procedure
(Douketis et al. 2012; Healey et al. 2012). Clinicians
must decide which patients require interruption of their
anticoagulation therapy, timing of any interruption and
whether to substitute a usual anticoagulant with a short-
acting alternative. Reviews and guidelines published to
support this decision-making process have been based on
expert opinion and observational studies, and calls for
further research and high quality trials have been made
by many (Douketis et al. 2012; Wysokinski et al. 2008;
Garcia et al. 2008; Eckman 2005; Ickx and Steib 2006).
Main text
New research
Douketis et al. present the first randomised controlled
trial of the benefits and risks of bridging anticoagulation
(Douketis et al. 2015). Patients (N = 1884) with AF had
their warfarin stopped 5 days before surgery and received
either twice daily dalteparin (100 units kg−1) or placebo
from 3 days until 1 day before surgery. Warfarin was
restarted on the day of or the day after surgery. Dalteparin
or placebo was restarted at 12–24 or 48–72 h after surgery
for low or high bleeding risk procedures respectively and
was continued until the INR was 2.0 or higher.
The primary efficacy outcome was the incidence of arter-
ial thromboembolism (ATE) at 30 days (stroke, systemic
embolism, transient ischaemic attack), and the primary
safety outcome was major bleeding at 30 days. The authors
performed a one-sided ‘non-inferiority’ test within a margin
of 1 % of placebo to dalteparin comparing ATE rates. A
two-sided ‘superiority’ test was performed to compare
major haemorrhage rates. The study had 90 % power for
the two primary end points.
Results
The incidences of ATE were 0.3 % with dalteparin and
0.4 % with placebo; placebo was non-inferior to dalte-
parin (P < 0.01). The incidences of major haemorrhage
were 3.2 % with dalteparin and 1.3 % with placebo; pla-
cebo was superior to dalteparin (P < 0.005).
Critique
Perioperative staff commonly face uncertainty as to the best
management strategy for patients, presenting for surgery,
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who are taking warfarin for AF. This study addresses an
important and common issue that has previously lacked
high-quality research.
Some issues with the study design and conclusions
have been raised (Duca et al. 2016). On closer examination
of the study population, less than 3 % of patients had the
highest CHADS2 scores of 5 or 6. These patients have the
highest annualised stroke risk (at 12–18 %) and would
potentially benefit most from perioperative bridging antic-
oagulation (Gage et al. 2001). In addition, many surgical
procedures associated with high rates of ATE were not
represented at all, including carotid endarterectomy and
major cancer surgery. Concluding that omission of bridging
anticoagulation is non-inferior to use of bridging
anticoagulation for all may cause disadvantage to these
high-risk groups.
The diagnosis of ATE within the protocol required
development and recognition of clinical symptoms. Silent
ATE occurs more commonly than overt ATE and is asso-
ciated with long-term complications (Sacco et al. 2013;
Fanning et al. 2014). The results may therefore not reflect
the true impact of omitting bridging anticoagulation.
The vast majority of procedures performed were asso-
ciated with a low risk of bleeding, and almost 40 % of
patients underwent minor gastrointestinal procedures
including endoscopy. Preexisting guidelines state that
such procedures may be performed without interruption
of oral anticoagulation (Veitch et al. 2008). Without fur-
ther information on the exact procedures carried out, and
without subgroup analysis, it is difficult to know if the
major conclusions apply to particular patient populations.
The study protocol randomised patients to receive high-
dose dalteparin or placebo. In practice, if warfarin was
withheld and high-dose dalteparin was not to be given,
many hospital guidelines would advocate administration of
lower dose low molecular weight heparin for venous
thromboembolism prophylaxis (www.guysandstthomas.nh
s.uk/resources/our-services/acute-medicine-gi-surgery/eld
erly-care/periop-warfarin-adults.pdf) Accessed 2 Feb
2016). How the results of the BRIDGE study would
affect these recommendations is unclear. Also, this study
did not investigate newer anticoagulants, which are in-
creasingly popular and have shorter half-lives (Baron et al.
2013). The ability to continue these agents closer to the
time of surgery may reduce or eliminate the requirement
for bridging anticoagulation therapy.
The authors understandably tested at a 1 % margin for
a one-sided hypothesis of non-inferiority of placebo to
dalteparin with regard to the incidence of ATE. How-
ever, their use of the term ‘superiority’ for the two-sided
hypothesis for haemorrhage is a common misuse of the
term, as ‘superiority’ is also a one-sided hypothesis. The
two-sided hypothesis is simply the standard ‘inequality’
hypothesis when the usual null hypothesis is rejected
(Columb and Lutz 2009). Another, not uncommon prob-
lem in RCTs that the authors had to deal with was the
lower than expected event rates for ATE. However, an
advantage with non-inferiority designs is that the study
remained adequately powered as the non-inferiority margin
of 1 % became proportionately larger with respect to the
lower incidence rates.
Conclusion
This is the first reported large, multicentre, randomised,
double-blind, placebo-controlled trial into perioperative
bridging anticoagulation. Its findings that bridging antic-
oagulation may be of no benefit in preventing ATE and
may increase incidence of bleeding are consistent with earl-
ier observational studies. Although some methodological
issues are present, its overall conclusions are important and
highly relevant to the perioperative physician.
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